Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.64Last Year’s EPS
-0.68Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 21, 2025
|% Change Since: -2.40%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for MediWound. While there are significant advancements in clinical trials and strategic collaborations, financial metrics reveal challenges with declining revenue and increased losses. However, the strong growth in NexoBrid's adoption and the strategic initiatives for EscharEx show promise for future performance.Company Guidance
During the MediWound First Quarter 2025 Earnings Call, the company provided several performance metrics and guidance updates. MediWound reported a total revenue of $4 million for the first quarter, down from $5 million in Q1 2024, with a gross profit of $0.7 million, reflecting a gross margin of 19%. Research and development expenses increased to $2.9 million due to ongoing investment in the EscharEx VALUE Phase III trial. The operating loss for the quarter was $5.2 million, while the net loss was $0.7 million or $0.07 per share, significantly improved from a net loss of $9.7 million or $1.05 per share in the prior year, primarily due to non-cash financial income from warrant revaluation. As of March 31, 2025, the company held $38.7 million in cash and equivalents, using $5.1 million to fund operations during the quarter. Looking forward, the company is on track with its clinical trials and manufacturing expansions, expecting EscharEx's interim analysis by mid-2026, while anticipating commercial availability of NexoBrid from the new facility by 2026, post regulatory approvals.Strong Phase III Progress for EscharEx
The VALUE Phase III study for EscharEx is on track with recruitment for venous leg ulcers progressing as planned. The trial will enroll 216 patients across 40 sites in the US and Europe, with results expected to support regulatory submissions and commercial positioning.
NexoBrid Global Expansion
US adoption of NexoBrid continues to expand with a 207% year-over-year increase and a 31% sequential increase in revenue. There is high demand in Japan and Europe, with manufacturing capacity expansion underway.
Strategic Collaborations
Collaboration with major wound care companies, including Kerecis, Mölnlycke, and MIMEDX, adds significant validation to MediWound's clinical programs, particularly for EscharEx.
European Innovation Council Grant
Secured a EUR2.5 million grant component for the clinical and regulatory advancement of EscharEx for diabetic foot ulcers.
MDWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MDWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 21, 2025 | $20.87 | $19.89 | -4.70% |
Mar 19, 2025 | $19.27 | $18.28 | -5.14% |
Nov 26, 2024 | $17.33 | $16.90 | -2.48% |
Aug 14, 2024 | $18.21 | $17.47 | -4.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mediwound (MDWD) report earnings?
Mediwound (MDWD) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Mediwound (MDWD) earnings time?
Mediwound (MDWD) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDWD EPS forecast?
MDWD EPS forecast for the fiscal quarter 2025 (Q2) is -0.64.